Lotte Biologics Wins CDMO Leadership Award, Proving Global Quality Management

Lotte Biologics announced on March 26 that it has won an award at the "2026 CDMO Leadership Awards," a globally recognized event in the contract development and manufacturing organization (CDMO) sector.

Shin Youl, CEO of Lotte Biologics (fifth from the left), and James Park, CEO of Lotte Biologics (sixth from the left), are taking a commemorative photo with employees. Lotte Biologics

The "CDMO Leadership Awards" is an internationally esteemed ceremony hosted by Outsourcing Pharma and Life Science Connect. Companies are selected based on evaluations from decision-makers at global pharmaceutical and biotechnology companies who have collaborated with nominees within the past 24 months. Winners are recognized for outstanding performance in areas such as capabilities, compatibility, expertise, quality, reliability, and service. Notably, starting this year, an independent review by the Tufts Center for the Study of Drug Development has been added, further enhancing the objectivity and credibility of the evaluation process.

Lotte Biologics was selected in the "Best New or Relaunched CDMO" category, which is determined by a panel of judges. This category recognizes companies that have either successfully entered the market or restructured their businesses, and have earned high trust from global partners based on distinctive competitiveness and a clear strategy.

The company stated that this award is especially meaningful as it comes just four years after its founding, demonstrating both the rapid expansion of its brand recognition in the global market and direct acknowledgment from clients for the quality and execution capabilities of its CDMO services.

In particular, the industry is highlighting the success of Lotte Biologics' "Dual Site" strategy. Leveraging experience with approvals from over 62 global regulatory agencies and the expansion of ADC (antibody-drug conjugate) modalities, the company has earned strong trust and positive evaluations from global clients, thus proving its competitiveness.

Lotte Biologics is expected to rapidly expand its business portfolio from antibody drugs to ADCs, emerging as a key player in the next-generation bio market, with the Songdo Bio Campus Plant 1 scheduled for completion in August this year as its foundation.

A Lotte Biologics representative commented, "It is very meaningful to receive such a credible award as a CDMO company in the global market in such a short time since our launch," adding, "We will continue to strengthen our role and responsibility as a leading company that adds real value to the global bio ecosystem, going beyond mere growth in scale."

Meanwhile, during this DCAT Week, Lotte Biologics is operating an exclusive meeting room at the Lotte Palace Hotel in New York, actively engaging in business discussions to expand strategic partnerships with global big pharma and biotech companies.

This content was produced with the assistance of AI translation services.